October 1, 2018

Trefoil Therapeutics, Inc.

Developer of novel engineered compounds designed to corneal dystrophies, improve human health and create new therapies using drugs developed with protein engineering. The company's therapeutic application is developed using a regenerative approach based on novel engineered derivatives of fibroblast growth factor-1 (eFGF-1) to treat endothelial cell mediated diseases, including Fuchs dystrophy and other serious endothelial cell diseases.